<DOC>
	<DOCNO>NCT00852787</DOCNO>
	<brief_summary>The purpose study examine effect digibind drug hemodialysis patient high blood pressure . Digibind use treat toxicity digoxin digoxin-like molecule may contribute high blood pressure .</brief_summary>
	<brief_title>Marinobufagenin Target DIGIBIND Hypertensive Patients With End-stage Renal Disease</brief_title>
	<detailed_description>High blood pressure common problem patient kidney disease . Researchers note certain molecule blood patient may contribute high blood pressure . In particular molecule label `` digoxin-like substance . '' Digoxin drug make certain plant may contribute high blood pressure . In research animal kidney failure , note use Digibind help low blood pressure animal . Digibind drug make sheep use treat toxicity digoxin well toxicity molecule similar digoxin . In study , volunteer hemodialysis high blood pressure give placebo digibind drug intravenously two separate visit . The volunteer wear 24-hour blood pressure monitor return follow day . Volunteers receive Digibind one visit study , placebo visit .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Bufanolides</mesh_term>
	<mesh_term>Marinobufagenin</mesh_term>
	<criteria>Aged 1875 year age On hemodialysis predialysis BP &gt; 150/90 â‰¤ 180/110 On least one antihypertensive medication 6 consecutive reading Able blood pressure measure arm Women child bear potential must pregnant ; must use contraception study one month study Receiving adequate dialysis ( KT/V &gt; 1.2 ) Compliant dialysis schedule duration Pregnant nursing woman Arm blood pressure possible obtain Currently digitalis On Digibindtype product past History allergy antibiotics History asthma Medical psychiatric disorder unstable might interfere study assessment safe participation study History use , evidence need , digitalislike product Inability understand provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Digoxin like substance</keyword>
	<keyword>digibind</keyword>
	<keyword>digoxin immune fab</keyword>
	<keyword>end-stage-renal-disease</keyword>
	<keyword>marinobufagenin</keyword>
</DOC>